AC
ZNTL icon

Athanor Capital’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Athanor Capital’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,520
Closed -$287K – 1075
2020
Q4 		$287K Buy
+5,520
New +$249K 0.01% 580

Other funds holding ZNTL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Athanor Capital's ZNTL Position: Q1 2021 in Review

Athanor Capital sold out of Zentalis Pharmaceuticals (ZNTL) in Q1 2021, closing a stake of 5,520 shares — an estimated $287K sold.

Athanor Capital first reported a position in ZNTL in Q4 2020 and held it in 1 quarter. The position peaked at $287K in Q4 2020. 95 funds tracked by Wall St. Rank hold ZNTL as of Q1 2021.

  • Athanor Capital reported no remaining Zentalis Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Athanor Capital sold 5,520 Zentalis Pharmaceuticals shares in Q1 2021, an estimated $287K.
  • Athanor Capital first reported a position in Zentalis Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Athanor Capital's Zentalis Pharmaceuticals position peaked at $287K in Q4 2020.
  • 95 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2021.

Based on Athanor Capital's 13F filing for Q1 2021, filed 14 May 2021.